The problem. Spot-based capture (Ståhl/Visium) is whole-transcriptome but coarse — 55-micron spots spanning several cells. Imaging is precise but targeted. Could a capture method — keeping the unbiased whole-transcriptome advantage — reach near-cellular resolution, getting the best of both branches without imaging’s panel limits?

The idea. Slide-seq packs a surface with 10-micron barcoded beads, each bead’s spatial position determined in advance by sequencing. Tissue laid on top releases mRNA captured by the nearest bead, so transcripts get near-cellular spatial coordinates while retaining whole-transcriptome capture. Slide-seqV2 improves the sensitivity (capture efficiency) enough to make the approach genuinely usable.

Why it matters. Slide-seqV2 sits right between the two poles I’ve read today — capture-based like Visium, but approaching imaging’s resolution. For the STU, it’s a key point on the platform trade-off curve: whole-transcriptome and fine-grained, at the cost of per-bead sensitivity and some deconvolution still needed. It shows the “capture vs. image” dichotomy is really a continuum.

Verdict. Foundational for high-resolution capture-based spatial; sensitivity per bead remains the practical constraint. Read it as the resolution upgrade to the Ståhl/Visium lineage, and as evidence that the capture branch can chase single-cell resolution too.